Zura Bio Shares Plunge After Skin Disease Drug Fails Mid-Stage Trial

Zura Bio (ZURA) said its experimental drug failed the main goal of a mid-stage study in patients with hidradenitis suppurativa, a chronic skin disease that causes painful lumps under the skin. Shares in the biotech group fell more than 75 per cent in morning trading.
The company said tibulizumab failed to show a benefit over placebo in reducing abscesses and inflammatory skin nodules after 16 weeks. Key secondary goals were also missed, including measures tracking the proportion of patients achieving at least 50 per cent and 75 per cent reductions in disease lesions.
The trial enrolled 247 adults with moderate-to-severe hidradenitis suppurativa, randomly assigned to receive one of two doses of tibulizumab or placebo. The two doses reduced lesion counts by 56 per cent and 58.1 per cent respectively, versus a 52.5 per cent reduction in the placebo group. Zura said the drug was well tolerated, while one death in the higher-dose group was considered unrelated to treatment by the study investigator.
Zura will discontinue development of tibulizumab for hidradenitis suppurativa but continue studying it in systemic sclerosis, which can cause hardening of the skin and internal organs, and polymyalgia rheumatica, an inflammatory condition causing muscle pain and stiffness.
The company had $187.7mn in cash and cash equivalents as of September 30, which it expects will support planned operations through at least the end of 2028.
Martin Fan, an analyst at Wedbush, said the selloff was overdone, pointing to Zura’s cash position of $1.47 per share and a systemic sclerosis study readout in the first half of 2027 that he said was uncorrelated with the failed skin disease trial.